Lumos Diagnostics Holdings Limited (LDXHF)

Market Cap	140.09M +1,317.6%
Revenue (ttm)	12.21M -16.7%
Net Income	-9.26M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	194,710
Average Volume	45,267
Open	0.1953
Previous Close	0.2400
Day's Range	0.1750 - 0.1953
52-Week Range	0.0100 - 0.2400
Beta	0.61
RSI	47.27
Earnings Date	May 27, 2026

About LDXHF

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platfor...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: OTCMKTS
• Ticker Symbol: LDXHF

Financial Performance

In fiscal year 2025, LDXHF's revenue was $12.40 million, an increase of 11.40% compared to the previous year's $11.13 million. Losses were -$7.18 million, -16.40% less than in 2024.